8-K: Charlotte's Web Q4/FY25: BAT Deal, Medicare Pilot Boost

Charlotte's Web announced its Q4 and full-year 2025 financial results, highlighted by a strategic transaction with BAT and participation in a new CMMI Medicare pilot program.

Summary

• Consolidated net revenue for Q4 2025 was $13.3 million, up 4.7% year-over-year from $12.7 million in Q4 2024.
• Full year 2025 consolidated net revenue was $49.9 million, a 0.5% increase from $49.7 million in 2024, marking the first annual revenue increase since 2021.
• A transaction with BAT (British American Tobacco) involves the amendment and conversion of BAT's C$75.3 million (approximately US$54 million) convertible debenture, plus C$14.2 million (approximately US$10 million) in accrued interest, eliminating Charlotte's Web's largest outstanding balance sheet liability.
• BAT will make a concurrent additional equity investment of US$10 million (approximately C$13.9 million) via a private placement, resulting in BAT holding approximately 40% of the Company's common shares on a non-diluted basis.
• Charlotte's Web is participating as a CBD launch partner in the anticipated Centers for Medicare & Medicaid Innovations (CMMI) Medicare pilot program, starting with senior oncology patients in April 2026.
• DeFloria, a collaboration involving Charlotte's Web, received FDA clearance to proceed with Phase 2 clinical trials for AJA001, a treatment for irritability associated with autism spectrum disorder (ASD), with trials expected to initiate in mid-2026.
• Total selling, general, and administrative (SG&A) expenses for 2025 decreased by $11.3 million, or 21.2%, to $42.0 million, reflecting a 44.5% reduction over the past two years.
• Net loss for Q4 2025 was $11.5 million, or $(0.07) per share, compared to a net loss of $3.4 million, or $(0.02) per share, in Q4 2024.
• Adjusted EBITDA loss for Q4 2025 was $(4.4) million, compared with Adjusted EBITDA of $0.3 million in Q4 2024.
• Net cash used in operating activities declined to $1.9 million in Q4 2025, compared to $5.5 million in Q3 2025.
• Cash and cash equivalents as of December 31, 2025, were $8.0 million, down from $22.6 million at December 31, 2024.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a strategically strong filing despite mixed financial results. The significant debt reduction and new capital from BAT, coupled with groundbreaking regulatory and pharmaceutical advancements, position the company for substantial long-term growth and market leadership in the evolving CBD and cannabinoid sectors.

Positives

• The BAT transaction eliminates Charlotte's Web's largest outstanding balance sheet liability (US$54 million convertible debenture plus US$10 million accrued interest) and removes approximately $3 million in annual interest costs.
• A new US$10 million equity investment from BAT strengthens the Company's liquidity and working capital position.
• Charlotte's Web is a CBD launch partner for the CMMI Medicare pilot program, the first federal initiative for federally authorized CBD access for senior patients, beginning April 2026.
• Regulatory momentum is building with the HEMP Act and a Presidential Executive Order, signaling a potential turning point for the hemp-derived CBD industry.
• DeFloria, a collaboration utilizing Charlotte's Web's proprietary extract, received FDA clearance for Phase 2 clinical trials for AJA001, validating the Company's botanical science.
• Charlotte's Web holds exclusive commercial manufacturing rights for AJA001 upon potential FDA approval, representing a significant long-term revenue opportunity.
• The Company owns approximately one-third of DeFloria, providing direct participation in pharmaceutical development value creation.
• Successful execution of a comprehensive cost optimization strategy reduced SG&A expenses by $11.3 million (21.2%) in FY2025 and 44.5% over the past two years.
• In-house gummy manufacturing provided a net gross margin benefit in Q4 2025 and is expected to further support margin improvement as production scales, with 75% of total gummy production expected to transition in 2026.
• Net cash used in operating activities declined to $1.9 million in Q4 2025, demonstrating progress in converting earnings improvements into cash flow.

Negatives

• Net loss for Q4 2025 increased significantly to $11.5 million, compared to a net loss of $3.4 million in Q4 2024.
• Adjusted EBITDA loss for Q4 2025 was $(4.4) million, a decline from a positive Adjusted EBITDA of $0.3 million in Q4 2024.
• Adjusted EBITDA loss for FY 2025 was $(12.9) million, slightly worse than the $(12.6) million loss in FY 2024.
• Gross profit margin in Q4 2025 declined to 37.5% from 40.2% in Q4 2024, impacted by a $1.3 million inventory charge related to the disposal of legacy gummy product.
• Cash and cash equivalents decreased from $22.6 million at December 31, 2024, to $8.0 million at December 31, 2025.
• Total shareholders' equity was a deficit of $(2.0) million as of December 31, 2025.

Risks

• Completion of the Transaction with BAT is subject to TSX approval and the approval of Charlotte's Web shareholders.
• The anticipated CMMI Medicare pilot program may not proceed as expected, or its scope and impact may differ from current expectations.
• Regulatory regime changes, including those related to the HEMP Act or other federal frameworks, could impact the Company's operations, product eligibility, and market opportunities.
• The Company faces risks related to supply and distribution chains, revenue fluctuations, and the overall market for its products.
• Loss of customers and retail partners, as well as challenges in retaining and attracting talent, could adversely affect the business.
• There is inherent share price volatility, and the Company faces risks related to loss of proprietary information and product acceptance.
• The functionality and security of internet and system infrastructure are critical, and any failures could impact operations.
• The availability of adequate liquidity and capital to fund operations and business plans remains a risk.
• Crop risk, economic, and political considerations can impact the Company's agricultural and market operations.
• The timing and outcomes from DeFloria's clinical trials, including the strategic value for shareholders and potential commercial opportunities, are subject to uncertainties.

Future Outlook

Management expects gross margin to normalize toward the Company's historical 50% range as production efficiencies continue to scale, particularly with increased in-house gummy manufacturing. Quarterly SG&A is anticipated to remain in a normalized range of approximately $10 million to $11 million. The Company expects continued improvement in cash utilization due to a declining operating expense base, anticipated gross margin improvements, and steady consumer demand. The new BAT equity capital is expected to further strengthen liquidity. DeFloria anticipates initiating its Phase 2 clinical trial for AJA001 in mid-2026, and a broader expansion of the CMMI Medicare pilot program to additional Medicare beneficiary segments is expected in 2027.

Management Comments

• Bill Morachnick, CEO: "2025 was a defining year for Charlottes Web. Our participation as a launch partner for the CMMI Medicare pilot marks a landmark breakthrough, bringing physician-authorized CBD access into the healthcare system for seniors, with Charlottes Web at the forefront."
• Bill Morachnick, CEO: "We see this as an early model for potential healthcare integration across additional segments of Medicares approximately 67 million beneficiaries. Alongside the Presidential Executive Order and growing bipartisan momentum for a rational federal framework, we believe our industry is at a pivotal inflection point. Weve built this Company for moments exactly like this."
• Bill Morachnick, CEO: "Our partnership with Ajna and BAT through DeFloria demonstrates our leadership in advancing hemp-derived compounds from consumer wellness into FDA-regulated pharmaceutical development, and it reflects the same commitment to science-backed innovation that drives our core business."
• Erika Lind, CFO: "The new BAT Transaction will be transformational for our balance sheet, eliminating material liabilities and adding $10 million in additional capital. As we progress with this strengthened financial foundation to support the anticipated Medicare pilot launch, Charlottes Web will be well-positioned to convert strategic catalysts into sustainable long-term performance."
• Erika Lind, CFO: "With a significantly de-levered capital structure, our focus will shift entirely to operational execution and unlocking the value of our strategic positioning in botanical wellness."

Industry Context

StockSavvy.ai notes that the broader hemp-derived CBD industry is at a pivotal inflection point, driven by significant federal policy developments. The CMMI Medicare pilot program represents a landmark shift towards integrating CBD into mainstream healthcare, potentially opening a vast market of 67 million Medicare beneficiaries. The HEMP Act and a Presidential Executive Order signal growing bipartisan support for a clear federal regulatory framework, which could legitimize and expand the market for responsible CBD products, differentiating them from unregulated, potentially risky alternatives. This regulatory clarity is crucial for industry growth and investor confidence.

Comparison to Industry Standards

• The CMMI Medicare pilot program is the first federal initiative of its kind, positioning Charlotte's Web as a pioneer in federally authorized CBD access for senior patients, a unique opportunity not yet available to most competitors.
• DeFloria's AJA001 advancing to Phase 2 clinical trials via the FDA's Botanical Drug Pathway is a significant achievement, as few cannabinoid drug programs reach this stage, especially utilizing a multi-compound botanical approach rather than single-molecule synthetics, differentiating Charlotte's Web from companies focused solely on consumer products or synthetic cannabinoid development.
• The company's cost optimization strategy, reducing SG&A by 44.5% over two years, demonstrates strong operational discipline, which may exceed the efficiency gains seen in some less mature or less focused competitors in the evolving CBD market.
• The BAT transaction, leading to a 40% stake, is a substantial strategic investment from a major global tobacco company, indicating strong external validation and a potential competitive advantage in terms of capital and strategic alignment compared to smaller, independent CBD players.

Corporate Governance

Related Party Transactions

• A transaction with BT DE Investments Inc. (BAT), a subsidiary of British American Tobacco p.l.c., involves the amendment and conversion of BAT's outstanding C$75.3 million (approximately US$54 million) convertible debenture, in addition to all accrued interest (C$14.2 million, or approximately US$10 million).
• BAT will also make a concurrent additional equity investment of US$10 million (approximately C$13.9 million) by way of a private placement.
• Following completion, BAT will hold approximately 40% of the Company's then-issued and outstanding common shares on a non-diluted basis.

Stakeholder Impact

• **Shareholders**: Significant strengthening of shareholders' equity by eliminating the largest outstanding balance sheet liability and adding new capital. Potential for long-term value creation from strategic initiatives like the CMMI pilot and DeFloria's pharmaceutical development. However, existing shareholders will experience dilution from the new equity investment and the conversion of the debenture into common shares, leading to BAT holding 40% of the company.
• **Creditors**: The conversion of the C$75.3 million convertible debenture eliminates the company's largest outstanding balance sheet liability, significantly de-leveraging the capital structure and improving creditworthiness.
• **Customers**: Potential for expanded access to CBD products through the CMMI Medicare pilot program for senior patients, particularly in oncology, and broader Medicare beneficiaries in the future. Continued product innovation with new offerings like Brightside low-dose hemp THC gummies and functional mushroom products.
• **Employees**: Workforce optimization initiatives implemented in the second half of 2024 led to lower personnel costs, indicating past reductions. No new changes mentioned.
• **Regulatory Authorities**: The company is actively engaging with and benefiting from federal policy developments (CMMI, HEMP Act, Executive Order) that aim to establish clearer regulatory frameworks for hemp-derived CBD.

Next Steps

• Obtain TSX approval for the BAT transaction.
• Obtain shareholder approval for the BAT transaction at the Annual General and Special Meeting scheduled for on or about May 28, 2026.
• Initiate DeFloria's Phase 2 clinical trial for AJA001 in mid-2026.
• Continue the transition of gummy production to in-house manufacturing, with approximately 75% of total gummy production expected to transition in 2026.
• Work with Congress to update the statutory definition of hemp-derived cannabinoid products.
• Anticipate broader expansion of the CMMI Medicare pilot program to additional Medicare beneficiary segments in 2027.

Key Dates

Recommendation

The strategic developments outlined in the filing are transformative and significantly de-risk the company while opening substantial new market opportunities. The BAT transaction eliminates a major liability, injects new capital, and solidifies a key strategic partnership. Participation in the CMMI Medicare pilot program is a groundbreaking entry into the federally authorized healthcare market for CBD, with immense long-term potential. Furthermore, DeFloria's advancement to Phase 2 clinical trials validates the company's botanical science and offers a pathway to a multi-billion-dollar pharmaceutical market. While recent financial results show losses, the underlying operational improvements (cost reductions, manufacturing efficiencies) and these strategic catalysts position Charlotte's Web for a strong future trajectory, making it a compelling "Strong Buy" for long-term investors.

Keywords

CBD, hemp extract, wellness products, CMMI Medicare pilot, British American Tobacco, BAT, DeFloria, AJA001, autism spectrum disorder, ASD, HEMP Act, financial results, Q4 2025, full year 2025, revenue, EBITDA, cost optimization, regulatory developments, pharmaceutical development